# Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

> **NCT02589145** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Vorinostat
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Rituximab
- **DRUG:** Dexamethasone
- **DRUG:** Caphosol
- **DRUG:** Glutamine
- **DRUG:** Pyridoxine
- **DRUG:** Enoxaparin
- **PROCEDURE:** Stem Cell Transplant
- **DRUG:** Palifermin

## Key facts

- **NCT ID:** NCT02589145
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-22
- **Primary completion:** 2019-04-08
- **Final completion:** 2019-04-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Closed due to very slow accrual
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02589145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02589145, "Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02589145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*